Bolt Biotherapeutics is a private biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of cancer therapeutics. These systemically-administered, tumor-targeted Boltbody™ therapeutics unleash the immune system to induce anti-tumor immunity. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, professor of pathology and medicine, Stanford Medicine, and its platform is based on technology exclusively licensed from Stanford University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/05/19 | $54,000,000 | Series B |
Nan Fung Novo Holdings Vivo Capital | undisclosed |
| 07/02/20 | $93,500,000 | Series C |
Novo Holdings Pfizer Venture Investments Pivotal bioVenture Partners RA Capital Rock Springs Capital Samsara BioCapital Sofinnova Ventures  Surveyor Capital Vivo Capital | undisclosed |
